Agios Pharmaceuticals, Inc.
Price
Overview
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Leadership
Chief Executive Officer of Agios Pharmaceuticals, Inc..
History & business model
This section is waiting to be written.
InvestWiki is community-edited. Contribute a plain-English history of Agios Pharmaceuticals, Inc., its business model, key products, and controversies.